P1068: RISK‐ADJUSTED SAFETY ANALYSIS OF PACRITINIB IN PATIENTS WITH MYELOFIBROSIS
Vannucchi, A., Pemmaraju, N., Scott, B., Savona, M., Oh, S., Palandri, F., Al‐Ali, H. K., Sobas, M., McMullin, M. F., Gupta, V., Yacoub, A., Mesa, R., Buckley, S., Roman‐Torres, K., Verstovsek, S., Harrison, C.
Published in HemaSphere (23.06.2022)
Published in HemaSphere (23.06.2022)
Get full text
Journal Article
P1069: RETROSPECTIVE COMPARISON OF PATIENT OUTCOMES ON PACRITINIB VERSUS RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND THROMBOCYTOPENIA
Harrison, C., Bose, P., Mesa, R., Gerds, A., Oh, S., Kiladjian, J.-J., García-Gutierrez, V., Vannucchi, A., Scheid, C., Sobas, M., Verstovsek, S., Buckley, S., Roman-Torres, K., Mascarenhas, J.
Published in HemaSphere (23.06.2022)
Published in HemaSphere (23.06.2022)
Get full text
Journal Article
P1069: RETROSPECTIVE COMPARISON OF PATIENT OUTCOMES ON PACRITINIB VERSUS RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND THROMBOCYTOPENIA
Harrison, C., Bose, P., Mesa, R., Gerds, A., Oh, S., Kiladjian, J.‐J., García‐Gutierrez, V., Vannucchi, A., Scheid, C., Sobas, M., Verstovsek, S., Buckley, S., Roman‐Torres, K., Mascarenhas, J.
Published in HemaSphere (01.06.2022)
Published in HemaSphere (01.06.2022)
Get full text
Journal Article